Searched for
MANKIND PHARMA REVENUE GROWTH
Swara Baby files DRHP with Sebi for Rs 1,000 crore IPOSwara Baby has filed its DRHP with Sebi for a Rs 1,000 crore IPO, comprising a Rs 500 crore fresh issue and Rs 500 crore OFS. The hygiene p...- Battery recycler BatX Energies raises Rs 105 crore from IvyCap Ventures, othersBatX Energies has secured Rs 105 crore in a funding round led by IvyCap Ventures, with participation from existing investors. The startup s...
- Mankind Pharma partners Denovo Sciences for AI-led drug discoveryMankind Pharma has partnered with Denovo Sciences to accelerate drug discovery using artificial intelligence. This collaboration aims to si...
- Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discoveryMankind Pharma has joined forces with Denovo Sciences to revolutionize drug discovery using artificial intelligence. This strategic partner...
- June GST collections 13.9% to ₹1.95 lakh croreIndia's GST revenue surged 13.9% to ₹1.95 lakh crore in June, driven by a significant 34.6% jump in import tax collections. While domestic ...
- Delayed monsoon may weigh on auto demand, but long-term outlook stays strong: Aditya ShahA delayed monsoon poses a temporary challenge to rural auto demand, particularly for tractors and two-wheelers, but the sector's long-term ...
- Organised dairy sector may clock 13-15% revenue growth this fiscal: CrisilThe organized dairy industry in India is on track to achieve remarkable revenue growth, anticipated at 13-15% this fiscal year. Increased d...
- PayU India posts first full-year operating profit in FY26; revenue rises 13%During the second half of FY26, PayU India also exited certain "negative margin portfolios", impacting its sequential revenue growth. In th...
- Auto ancillary sector revenue grew 12.5% in FY26 on volume gains and improved product mix: ReportIndian auto ancillaries witnessed robust revenue growth of 12.5% in FY26, driven by strong volumes and a better product mix. While EBITDA a...
- Persistent's Nagarro deal could be a near-term pain for long-term gainPersistent Systems is acquiring Nagarro SE for $1.3 billion, aiming for European expansion and reduced US market reliance. While strategica...
- ITC's packaged foods business crosses $2 billion in revenueITC's packaged food business soared past $2 billion in FY26, with overall FMCG consumer spending reaching Rs 37,000 crore. This growth was ...
- Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improveLaurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
- Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
Load More
